Literature DB >> 14667503

Oct-3/4 is a dose-dependent oncogenic fate determinant.

Sharon Gidekel1, Galina Pizov, Yehudit Bergman, Eli Pikarsky.   

Abstract

The Oct-3/4 transcription factor sustains embryonic stem (ES) cell self-renewal and is a dose-dependent cell fate determinant. In the adult male, its expression is restricted to type A spermatogonia. We show that Oct-3/4 is expressed in all human testicular germ cell tumors (GCTs) tested, even in the early premalignant component. We demonstrate that Oct-3/4 dictates ES cells' oncogenic potential in a dose-dependent manner; high levels increase the malignant potential of ES cell-derived tumors while Oct-3/4 inactivation induces regression of the malignant component. Oct-3/4 expression in a heterologous cell system transforms nontumorigenic cells and endows tumorigenicity in nude mice. Our findings suggest that Oct-3/4 is not only a distinctive immunohistochemical marker for GCTs, but also plays a critical role in the genesis of these tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667503     DOI: 10.1016/s1535-6108(03)00270-8

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  160 in total

1.  Alpha1 and beta1 integrins enhance the homing and differentiation of cultured prostate cancer stem cells.

Authors:  Satyanarayana Rentala; Prameela Devi Yalavarthy; Lakshmi Narasu Mangamoori
Journal:  Asian J Androl       Date:  2010-06-07       Impact factor: 3.285

2.  NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53.

Authors:  Marie Zbinden; Arnaud Duquet; Aiala Lorente-Trigos; Sandra-Nadia Ngwabyt; Isabel Borges; Ariel Ruiz i Altaba
Journal:  EMBO J       Date:  2010-06-25       Impact factor: 11.598

Review 3.  Vaccines targeting cancer stem cells: are they within reach?

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

4.  Can antitumor immunity help to explain "oncogene addiction"?

Authors:  Nicholas P Restifo
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

Review 5.  Microinvasive germ cell tumor of the testis.

Authors:  Finn Edler von Eyben; Grete Krag Jacobsen; Rolf Inge Skotheim
Journal:  Virchows Arch       Date:  2005-06-21       Impact factor: 4.064

Review 6.  CD117(+) amniotic fluid stem cells: state of the art and future perspectives.

Authors:  Mara Cananzi; Paolo De Coppi
Journal:  Organogenesis       Date:  2012-07-01       Impact factor: 2.500

7.  Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus.

Authors:  Xiaochun Zhang; Ritsuko Komaki; Li Wang; Bingliang Fang; Joe Y Chang
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

8.  Differential expression profiling between atypical teratoid/rhabdoid and medulloblastoma tumor in vitro and in vivo using microarray analysis.

Authors:  Hsin-I Ma; Chung-Lan Kao; Yi-Yen Lee; Guang-Yuh Chiou; Lung-Kuo Tai; Kai-Hsi Lu; Chi-Shuan Huang; Yi-Wei Chen; Shih-Hwa Chiou; Ing-Chan Cheng; Tai-Tong Wong
Journal:  Childs Nerv Syst       Date:  2009-11-10       Impact factor: 1.475

Review 9.  Epigenetic reprogramming in cancer.

Authors:  Mario L Suvà; Nicolo Riggi; Bradley E Bernstein
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

Review 10.  Hypoxic tumor microenvironment and cancer cell differentiation.

Authors:  Yuri Kim; Qun Lin; Peter M Glazer; Zhong Yun
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.